To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults

Recruiting now · Phase 1

Conditions studied: Type 2 Diabetes, Dyslipidemias

In brief

The purpose of this study is to evaluate pharmacokinetic interaction and safety of co-administrated 25mg of Empagliflozin and 10/10mg Ezetimibe/Rosuvastatin in steady state in healthy volunteers.

Key facts

Study ID

NCT06578676

Run by

Hyundai Pharm

People needed

56

Starts

2024-06-20

Expected to finish

2024-11-30

Last updated by the study team

2024-08-29

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Signed informed consent
• Age: 19 and over , healthy volunteer
• Body mass index (BMI): 18.5≤BMI≤29.9 kg/m²

You may not qualify if…

• Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination or effects of the study drugs will not be normal
• Clinically relevant findings(e.g. blood pressure, electrocardiogram(ECG); physical and gynecological examination, laboratory examination)

Where it is running

• Kyungpook national university hospital — Daegu, Gyeongsangbuk-do, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.